公开(公告)号：JP2012072145A

公开(公告)日：2012-04-12

申请号：JP2011226490

申请日：2011-10-14

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： BAYBURT EROL K ,  DIDOMENICO STANLEY JR ,  DRIZIN IRENE ,  GOMTSYAN ARTHUR R ,  KOENIG JOHN R ,  PERNER RICHARD J ,  SCHMIDT ROBERT G JR ,  TURNER SEAN C ,  WHITE TAMMIE K ,  ZHENG GUO ZHU ,  LEE CHIH-HUNG

IPC: C07D209/08 ,  A61K31/404 ,  A61K31/416 ,  A61K31/454 ,  A61K31/46 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/502 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  A61P13/00 ,  A61P25/04 ,  A61P29/00 ,  A61P43/00 ,  C07D217/02 ,  C07D217/24 ,  C07D231/56 ,  C07D237/28 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D451/02

Abstract: PROBLEM TO BE SOLVED: To provide a novel VR1 antagonist useful for treatment of pain, inflammatory thermalgesia, urorrhea and bladder hyperactivity.SOLUTION: The compound is represented by formula (I) (wherein Xto Xare each a nitrogen atom or the like; R, Rand Rare each a hydrogen atom or the like; Zand Zare each an oxygen atom or the like; and L is an alkenylene or the like).

Abstract translation: 要解决的问题：提供一种新颖的VR1拮抗剂，可用于治疗疼痛，炎症性热痛，尿痛和膀胱多动症。 解决方案：化合物由式（I）表示（其中X 1 至X 5 分别为氮原子 每个都是R＆lt; SB POS =“POST”> 8a ，R 8b 和R 9 氢原子等; Z 1 ，Z 2 分别为氧原子等; L为亚烯基 或类似物）。 版权所有（C）2012，JPO＆INPIT

公开(公告)号：JP2012111766A

公开(公告)日：2012-06-14

申请号：JP2012003232

申请日：2012-01-11

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： GOMTSYAN ARTHUR R ,  BAYBURT EROL K ,  SCHMIDT ROBERT G JR ,  LEE CHIH-HUNG ,  BROWN S BRIAN ,  JINKERSON K TAMMIE ,  KOENIG R JOHN ,  DAANEN F JEROME ,  LATSHAW STEVE

IPC: C07D401/12 ,  A61K31/416 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/55 ,  A61P13/00 ,  A61P13/10 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P43/00 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12

CPC classification number: C07D405/12 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12

Abstract: PROBLEM TO BE SOLVED: To provide VR1 antagonists useful in treatment of pain and urinary disorders, especially acute pain, chronic pain, inflammatory pain, osteoarthritic pain, cancer pain, lumbago, neurogenic urinary bladder and urinary incontinence.SOLUTION: There are provided compounds represented by formula (I).

Abstract translation: 要解决的问题：提供可用于治疗疼痛和尿失禁，特别是急性疼痛，慢性疼痛，炎性疼痛，骨关节炎疼痛，癌症疼痛，腰痛，神经源性膀胱和尿失禁的VR1拮抗剂。 提供了由式（I）表示的化合物。 版权所有（C）2012，JPO＆INPIT

公开(公告)号：WO2006065484A3

公开(公告)日：2009-02-19

申请号：PCT/US2005042545

申请日：2005-11-22

Applicant: ABBOTT LAB ,  GOMTSYAN ARTHUR R ,  BAYBURT EROL K ,  SCHMIDT ROBERT G JR ,  LEE CHIH-HUNG ,  BROWN S BRIAN ,  JINKERSON K TAMMIE ,  KOENIG R JOHN ,  DAANEN F JEROME ,  LATSHAW STEVE

Inventor： GOMTSYAN ARTHUR R ,  BAYBURT EROL K ,  SCHMIDT ROBERT G JR ,  LEE CHIH-HUNG ,  BROWN S BRIAN ,  JINKERSON K TAMMIE ,  KOENIG R JOHN ,  DAANEN F JEROME ,  LATSHAW STEVE

IPC: C07D401/12 ,  A61K31/35 ,  A61K31/4709 ,  A61K31/5375 ,  A61P13/00 ,  A61P29/00 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12

CPC classification number: C07D405/12 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12

Abstract: Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

Abstract translation: 作为VR1受体的拮抗剂的化合物，其具有式（I）或其前药的药学上可接受的盐，前药或盐，其中A1，A2，A3，A4，R7，R8，R9，X，Y，Z， L，n和m如本文所定义，并且可用于通过抑制VR1受体而防止或改善的病症。

公开(公告)号：MXPA06001396A

公开(公告)日：2007-02-13

申请号：MXPA06001396

申请日：2004-08-04

Applicant: ABBOTT LAB

Inventor： BAYBURT EROL K ,  LEE CHIH-HUNG ,  KOENIG JOHN R ,  ZHENG GUO ZHU ,  TURNER SEAN C ,  WHITE TAMMIE K ,  DIDOMENICO STANLEY JR ,  DRIZIN IRENE ,  GOMTSYAN ARTHUR R ,  PENNER RICHARD J ,  SCHMIDT ROBERT G JR

IPC: C07D217/24 ,  A61K31/5377 ,  C07D209/08 ,  C07D217/02 ,  C07D217/22 ,  C07D217/26 ,  C07D231/56 ,  C07D237/28 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D451/02 ,  C07D521/00

Abstract: Ver formula (I) Los compuestos de la Formula (I) son novedosos antagonistas de VR1, que son utiles en el tratamiento de dolor, hiperalgesia termica inflamatoria, incontinencia urinaria, e hiperactividad de la vejiga.

公开(公告)号：ZA200601022B

公开(公告)日：2007-05-30

申请号：ZA200601022

申请日：2006-02-03

Applicant: ABBOTT LAB

Inventor： BAYBURT EROL K ,  IRENE DRIZIN ,  KOENIG JOHN R ,  SCHMIDT ROBERT G JR ,  WHITE TAMMIE K ,  CHIH-HUNG LEE ,  STANLEY DIDOMENICO JR ,  GOMTSYAN ARTHUR R ,  PENNER RICHARD J ,  TURNER SEAN C ,  ZHU ZHENG GUO

IPC: A61K20090101 ,  C07D20090101 ,  C07D209/08 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D217/26 ,  C07D231/56 ,  C07D237/28 ,  C07D401/12 ,  C07D405/12 ,  C07D521/00

Abstract: Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X 1 , X 2 , X 3 , X 4 , X 5 , R 5 , R 6 , R 7 , R 8a , R 8b , R 9 , Z 1 , Z 2 and L are as defined in the description.

公开(公告)号：BRPI0617884A2

公开(公告)日：2011-08-09

申请号：BRPI0617884

申请日：2006-10-27

Applicant: ABBOTT LAB

Inventor： GOMTSYAN ARTHUR R ,  BAYBURT EROL K ,  KOENIG JOHN R ,  MARSH KENNAN C ,  SCHMIDT ROBERT G JR ,  LEE CHIH-HUNG ,  WANG WEILI ,  DAANEN JEROME F ,  BROWN BRIAN S

IPC: C07D231/56 ,  A61K31/416 ,  A61P13/00 ,  C07D407/12

Abstract: Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.

公开(公告)号：AU2005316972A1

公开(公告)日：2006-06-22

申请号：AU2005316972

申请日：2005-11-22

Applicant: ABBOTT LAB

Inventor： SCHMIDT ROBERT G JR ,  LATSHAW STEVE ,  BROWN S BRIAN ,  GOMTSYAN ARTHUR R ,  DAANEN F JEROME ,  KOENIG R JOHN ,  JINKERSON K TAMMIE ,  BAYBURT EROL K ,  LEE CHIH-HUNG

IPC: A61K31/55

Abstract: Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt thereof, wherein A 1 , A 2 , A 3 , A 4 , R 7 , R 8 , R 9 , X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

公开(公告)号：CA2743534A1

公开(公告)日：2005-02-24

申请号：CA2743534

申请日：2004-08-04

Applicant: ABBOTT LAB

Inventor： LEE CHIH-HUNG ,  BAYBURT EROL K ,  DIDOMENICO STANLEY JR ,  DRIZIN IRENE ,  GOMTSYAN ARTHUR R ,  KOENIG JOHN R ,  PERNER RICHARD J ,  SCHMIDT ROBERT G JR ,  TURNER SEAN C ,  WHITE TAMMIE K ,  ZHENG GUO ZHU

IPC: C07D231/56 ,  A61K31/416 ,  A61K31/439 ,  A61K31/46 ,  A61K31/472 ,  A61K31/55 ,  A61P13/10 ,  C07D217/02 ,  C07D401/12 ,  C07D403/12 ,  C07D451/02 ,  C07D471/08

Abstract: Compounds of formula (I) (see formula (I)) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

公开(公告)号：CA2534542A1

公开(公告)日：2005-02-24

申请号：CA2534542

申请日：2004-08-04

Applicant: ABBOTT LAB

Inventor： WHITE TAMMIE K ,  ZHENG GUO ZHU ,  TURNER SEAN C ,  SCHMIDT ROBERT G JR ,  DRIZIN IRENE ,  PERNER RICHARD J ,  KOENIG JOHN R ,  GOMTSYAN ARTHUR R ,  DIDOMENICO STANLEY JR ,  BAYBURT EROL K ,  LEE CHIH-HUNG

IPC: C07D217/24 ,  A61K31/47 ,  A61K31/472 ,  A61K31/496 ,  A61K31/5377 ,  C07D209/08 ,  C07D217/02 ,  C07D217/22 ,  C07D217/26 ,  C07D231/56 ,  C07D237/28 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D451/02 ,  C07D521/00

Abstract: Compounds of Formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

公开(公告)号：CA2626593A1

公开(公告)日：2007-05-03

申请号：CA2626593

申请日：2006-10-27

Applicant: ABBOTT LAB

Inventor： WANG WEILI ,  DAANEN JEROME F ,  GOMTSYAN ARTHUR R ,  LEE CHIH-HUNG ,  BROWN BRIAN S ,  BAYBURT EROL K ,  SCHMIDT ROBERT G JR ,  KOENIG JOHN R ,  MARSH KENNAN C

IPC: C07D231/56 ,  A61K31/416 ,  A61P13/00 ,  C07D407/12

Abstract: Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.